HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.

The Journal of Antimicrobial Chemotherapy
Bénédicte RoquebertFrench ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)

Abstract

We investigated the in vitro phenotypic susceptibility of HIV-2 isolates from integrase inhibitor (INI)-naive patients to INIs and its relation to HIV-2 integrase gene polymorphism. We determined the phenotypic susceptibility to raltegravir and elvitegravir of co-cultured isolates obtained from the HIV-2 ROD reference strain and from 14 clinical isolates. IC(50) values were compared with those for HIV-1 reference strains. HIV-2 integrase gene polymorphism was assessed in isolates from 52 INI-naive patients enrolled in the French HIV-2 cohort. Median raltegravir and elvitegravir IC(50) values for the 14 clinical HIV-2 isolates were 2.4 and 0.7 nM, respectively, and were similar to those observed for HIV-2 ROD and HIV-1 reference strains. Overall, 38% of HIV-2 integrase amino acids were polymorphic. The catalytic triad DDE and the HHCC and RKK motifs were fully conserved, at the same genomic positions as described in HIV-1. In subtype B isolates, the total length of the integrase gene varied, owing to the presence of stop codons at positions 288, 294, 297 and 302. Fourteen of the positions associated with substitutions conferring INI resistance in HIV-1 were polymorphic in HIV-2. Despite 40% heterogeneity between the HIV-1 and HI...Continue Reading

References

Nov 3, 1993·JAMA : the Journal of the American Medical Association·K M De CockH D Gayle
Nov 26, 1996·Proceedings of the National Academy of Sciences of the United States of America·R ZhengR Craigie
Sep 26, 1997·AIDS·F B LilloO E Varnier
May 25, 2002·The Journal of General Virology·Jacqueline D Reeves, Robert W Doms
May 12, 2004·Current Topics in Medicinal Chemistry·Thang K Chiu, David R Davies
Aug 6, 2005·Journal of Clinical Microbiology·Florence DamondFrancoise Brun-Vezinet
Mar 3, 2006·Journal of Medicinal Chemistry·Motohide SatoHisashi Shinkai
Jan 30, 2008·Antimicrobial Agents and Chemotherapy·Delphine DesboisUNKNOWN French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)

❮ Previous
Next ❯

Citations

Jul 22, 2009·AIDS Research and Human Retroviruses·Li XuErasmus Smit
Feb 23, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Charlotte CharpentierMartin Obermeier
Dec 6, 2011·The Journal of Infectious Diseases·Benoit VisseauxUNKNOWN ANRS CO 05 HIV-2 Cohort
Dec 18, 2009·The Journal of Antimicrobial Chemotherapy·Carolina GarridoCarmen de Mendoza
Sep 21, 2010·The Journal of Antimicrobial Chemotherapy·William G Powderly
May 12, 2011·The Journal of Antimicrobial Chemotherapy·Ana TreviñoUNKNOWN HIV-2 Spanish Study Group
Sep 10, 2010·AIDS·Charlotte CharpentierUNKNOWN French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
Oct 6, 2011·AIDS·Robert A SmithUNKNOWN University of Washington-Dakar HIV-2 Study Group
Oct 22, 2010·HIV Medicine·Y GilleeceUNKNOWN BHIVA Guidelines Subcommittee
May 28, 2009·Antimicrobial Agents and Chemotherapy·Michel L NtemgwaMark A Wainberg
Apr 11, 2013·Antimicrobial Agents and Chemotherapy·Dana N RaugiUNKNOWN University of Washington-Dakar HIV-2 Study Group
Dec 30, 2010·Antimicrobial Agents and Chemotherapy·Charlotte CharpentierUNKNOWN French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
Nov 9, 2011·Antimicrobial Agents and Chemotherapy·Benoit VisseauxUNKNOWN French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
Jan 29, 2011·Journal of Virology·Yasuhiro KohAlan Engelman
Jan 31, 2012·Intervirology·Ricardo Jorge Camacho
Dec 25, 2012·BMC Infectious Diseases·Miłosz ParczewskiAnna Boroń-Kaczmarska
Dec 1, 2010·Retrovirology·Danielle Perez BercoffJean Ruelle
Apr 7, 2010·European Journal of Medical Research·Jean-Francois Mouscadet, Luba Tchertanov
Jul 19, 2011·PloS One·Geoffrey S GottliebUNKNOWN Papa Salif Sow for the UW-Dakar HIV-2 Study Group
Aug 10, 2010·Core Evidence·Kavya Ramkumar, Nouri Neamati
Jan 1, 2010·Infection and Drug Resistance·Charlotte Charpentier, Laurence Weiss
Oct 14, 2011·Viruses·Karoll J Cortez, Frank Maldarelli
Oct 1, 2009·Future Medicinal Chemistry·Arnout Rd VoetFrauke Christ
Dec 3, 2014·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Wan-Gang Gu
Dec 19, 2013·Antiviral Research·Luis Menéndez-Arias, Mar Alvarez
Mar 4, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Omobolaji T Campbell-Yesufu, Rajesh T Gandhi
Jun 24, 2014·Enfermedades infecciosas y microbiología clínica·UNKNOWN Panel de expertos de GeSIDA, UNKNOWN Plan Nacional sobre el Sida
May 3, 2014·The Journal of Antimicrobial Chemotherapy·Ana TreviñoUNKNOWN HIV-2 Spanish Study Group
Nov 19, 2008·Clinical Therapeutics·Jennifer Cocohoba, Betty J Dong
Aug 17, 2010·Expert Opinion on Investigational Drugs·Nicole Prada, Martin Markowitz
Oct 29, 2013·Enfermedades infecciosas y microbiología clínica·UNKNOWN Panel de expertos de GeSIDA y Plan Nacional sobre el Sida
Jun 24, 2010·Enfermedades infecciosas y microbiología clínica·Ana TreviñoUNKNOWN Grupo Español para el Estudio del VIH-2 y HTLV
Dec 8, 2009·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Sophie StegmannChristophe Piketty
Aug 12, 2009·Antiviral Research·Laura DickinsonDavid Back
Jul 25, 2009·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·María SalgadoBerta Rodés
Jun 30, 2009·Medicina clínica·Ana TreviñoUNKNOWN Grupo Español para el Estudio del VIH-2 y HTLV-1/2
May 12, 2015·Enfermedades infecciosas y microbiología clínica·UNKNOWN Panel de expertos de GeSIDA y Plan Nacional sobre el Sida
Apr 15, 2011·AIDS Research and Treatment·Kevin PetersonThushan I de Silva

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.